



Definitive Notice of the Interim Result

of the public tender offer by

Danaher Corporation, a Delaware corporation having its principal place of business in Washington, D.C., USA

for all publicly held registered shares with a nominal value of CHF 0.40 each of

Nobel Biocare Holding AG, Kloten, Switzerland

On 1 October 2014, Danaher Corporation, Washington, D.C., USA (**Danaher**), published the offer prospectus (the **Offer Prospectus**) for its public tender offer (the **Offer**) in accordance with article 22 et seq. of the Federal Stock Exchange and Securities Trading Act (*Bundesgesetz über die Börsen und den Effektenhandel*) for all publicly held registered shares of Nobel Biocare Holding AG, Kloten, Switzerland (**Nobel Biocare**), with a nominal value of CHF 0.40 each (each, a **Nobel Biocare Share**). The offer price for each Nobel Biocare Share amounts to CHF 17.10 net in cash, less the gross amount of any dilution effects becoming effective prior to the settlement of the Offer, as further described in the Offer Prospectus.

Interim Result

The participation of Danaher and the persons acting in concert with Danaher as of the end of the offer period on 14 November 2014, 4:00 p.m. CET (the **Offer Period**), is 97,196,634 Nobel Biocare Shares in total, corresponding to 78.52 % of the voting rights and the share capital of Nobel Biocare registered in the commercial register (participation rate), and consists of:

- a total of 72,001,022 Nobel Biocare Shares which were tendered into the Offer until the expiration of the Offer Period, corresponding to 60.97 % of the 118,095,706 Nobel Biocare Shares to which the Offer relates (success rate);
- 5,688,824 Nobel Biocare Shares which Danaher and the persons acting in concert with Danaher held as of 26 September 2014; and
- 19,506,788 Nobel Biocare Shares which Danaher and the persons acting in concert with Danaher purchased outside the Offer after such date until the expiration of the Offer Period.

The following overview illustrates the interim result:

| | Number of Nobel Biocare Shares | Share capital/ Voting rights (participation rate) | Success rate |
|---|-----------------------------------|---|-----------------|
| Nobel Biocare Shares tendered into the Offer | 72,001,022 | 58.17 % | 60.97 % |
| Nobel Biocare Shares held by Danaher and the persons acting in concert with Danaher as of 26 September 2014 | 5,688,824 | 4.60 % | |
| Nobel Biocare Shares purchased by Danaher and the persons acting in concert with Danaher outside the Offer until the expiration of the Offer Period | 19,506,788 | 15.76 % | |
| Interim result | 97,196,634 | 78.52 % | |

Satisfaction of the Conditions

At the end of the Offer Period, the conditions (a) and (d) according to Section B.7 (*Conditions*) of the Offer Prospectus are satisfied. The conditions (b), (c), (e), (f) and (g) according to Section B.7 (*Conditions*) of the Offer Prospectus remain in place, as set forth in Section B.7 (*Conditions*) of the Offer Prospectus.

In relation to condition (b), Danaher has received approvals from the competent merger control authorities, or the applicable waiting periods have expired, in all jurisdictions in which Danaher filed for merger clearance.

Subject to the satisfaction of the conditions (b), (c), (e), (f) and (g) according to Section B.7 (*Conditions*) of the Offer Prospectus, Danaher declares the Offer successful.

Additional Acceptance Period and Settlement

In accordance with Section B.6 (*Additional Acceptance Period*) of the Offer Prospectus, the additional acceptance period of 10 trading days for the subsequent acceptance of the Offer will start on 21 November 2014 and run until 4 December 2014, 4:00 p.m. CET.

Subject to the satisfaction of all conditions and a postponement of the settlement in accordance with Section B.7 (*Conditions*) of the Offer Prospectus, the settlement is expected to occur on 11 December 2014.

Squeeze-out and De-listing

As further described in the Offer Prospectus, Danaher among other things reserves the right to have Nobel Biocare apply with SIX Swiss Exchange for the de-listing of the Nobel Biocare Shares and to request the cancellation of non-tendered Nobel Biocare Shares, or to compensate shareholders of non-tendered Nobel Biocare Shares in the context of a squeeze-out merger, if

the legal requirements are met (cf. Section E.3 (*Intentions of Danaher with respect to Nobel Biocare*) and Section L.6 (*Squeeze-out and De-listing*) of the Offer Prospectus).

Acceptance of the Offer

Shareholders who intend to accept the Offer during the additional acceptance period are invited to proceed according to the instructions of their depository bank.

Offer Restrictions

The Offer is subject to the offer restrictions set forth in the Offer Prospectus. The Offer Prospectus may be obtained without delay and free of charge in German, French and English from Credit Suisse AG, Zurich (tel.: +41 (0)44 333 43 85; fax: +41 (0)44 333 35 93; e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and all other Offer documents are accessible under <http://phx.corporate-ir.net/phoenix.zhtml?c=82105&p=irol-irhome>.

| Nobel Biocare Holding AG | Swiss Security Number | ISIN | Ticker Symbol |
|---|-----------------------|--------------|---------------|
| Registered shares not tendered (first trading line) | 3785164 | CH0037851646 | NOBN |
| Registered shares tendered (second trading line) | 25474182 | CH0254741827 | NOBNE |

20 November 2014

Financial Advisor and Offer Manager

Credit Suisse